Brief: Chiesi Global Rare Diseases And Protalix Biotherapeutics Seek Re-Examination From The EMA For The Negative Opinion For Elfabrio (Pegunigalsidase Alfa) Alternative Dosing Regimen Of Every Four Weeks In The EU

Protalix BioTherapeutics

03/11/2025 23:06

Nov 4 (Reuters) - Protalix Biotherapeutics Inc PBDA.F:

CHIESI GLOBAL RARE DISEASES AND PROTALIX BIOTHERAPEUTICS SEEK RE-EXAMINATION FROM THE EMA FOR THE NEGATIVE OPINION FOR ELFABRIO (PEGUNIGALSIDASE ALFA) ALTERNATIVE DOSING REGIMEN OF EVERY FOUR WEEKS IN THE EU

CHIESI GLOBAL RARE DISEASES - PROPOSED DOSING REGIMEN OF 2 MG/KG EVERY 4 WEEKS FOR ELFABRIO

CHIESI GLOBAL RARE DISEASES - EXISTING MARKETING AUTHORIZATION FOR ELFABRIO REMAINS IN EFFECT

Source text: ID:nGNX5spTtR

Further company coverage: PBDA.F

 ((Reuters.Briefs@thomsonreuters.com;))